Figure 1. Relationships among high K + :Cl – cotransport activity, increased cell density, HbF, and oxyHbC crystallization in HbSC disease. Increasing HbF by gene therapy should decrease HbS polymerization tendency and oxyHbC crystallization, thereby reducing the density of the HbSC erythrocyte... More about this image found in Relationships among high K + :Cl – cotransport activity, increased cell de...

Figure 1. CONSORT diagram summarizing patients diagnosed with cTTP, consented, and followed up, in addition to previous and current prophylactic therapy. More about this image found in CONSORT diagram summarizing patients diagnosed with cTTP, consented, and fo...

Figure 1. Response and survival outcomes according to fitness status. Blue bars and curves represent fit patients; red bars and curves represent unfit patients. (A) ORRs in fit and unfit patients. (B) MRD rates in fit and unfit patients. (C) PFS in fit and unfit patients. (D) OS in fit and unfit... More about this image found in Response and survival outcomes according to fitness status. Blue bars and ...

Figure 2. Frequency of AEs according to fitness status. Blue bars and curves represent fit patients; red bars and curves represent unfit patients. AEs are categorized by preferred terms according to Medical Dictionary for Regulatory Activities (MedDRA) coding. More about this image found in Frequency of AEs according to fitness status. Blue bars and curves represe...

Figure 3. Landmark survival analyses according to treatment completion status. Blue curves represent patients with early EOT; red curves represent patients with regular EOT. (A) Landmark PFS from EOT. (B) Landmark OS from EOT. More about this image found in Landmark survival analyses according to treatment completion status. Blue ...

Figure 4. Response and landmark survival outcomes according to dose intensity. Blue bars and curves represent patients with a venetoclax dose intensity of ≥70%; red bars and curves represent patients with a venetoclax dose intensity of <70%. (A) ORRs. (B) MRD rates. (C) Landmark PFS from EOT.... More about this image found in Response and landmark survival outcomes according to dose intensity. Blue ...

Figure 1. CONSORT diagram. The diagram shows the distribution of patients who developed their first AAP during each treatment phase and the occurrence of a second AAP after asparaginase rechallenge in LR, IR, and HR patients. More about this image found in CONSORT diagram. The diagram shows the distribution of patients who develo...